Among them, genetic alterations leading to abnormal activations of the Ras signaling pathway represent the most common oncogenic driver mutations, particularly BRAF and NRAS mutations, which occur in approximately 50% and 15% of melanomas, respectively (34). This evidence concerns the gene NRAS and melanoma.